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Abstract
Objectives To describe how the methodological quality of
primary studies is assessed in systematic reviews and whether
the quality assessment is taken into account in the
interpretation of results.
Data sources Cochrane systematic reviews and systematic
reviews in paper based journals.
Study selection 965 systematic reviews (809 Cochrane reviews
and 156 paper based reviews) published between 1995 and
2002.
Data synthesis The methodological quality of primary studies
was assessed in 854 of the 965 systematic reviews (88.5%). This
occurred more often in Cochrane reviews than in paper based
reviews (93.9% v 60.3%, P < 0.0001). Overall, only 496 (51.4%)
used the quality assessment in the analysis and interpretation of
the results or in their discussion, with no significant differences
between Cochrane reviews and paper based reviews (52% v
49%, P = 0.58). The tools and methods used for quality
assessment varied widely.
Conclusions Cochrane reviews fared better than systematic
reviews published in paper based journals in terms of
assessment of methodological quality of primary studies,
although they both largely failed to take it into account in the
interpretation of results. Methods for assessment of
methodological quality by systematic reviews are still in their
infancy and there is substantial room for improvement.
Introduction
Critical appraisal of the methodological quality of primary stud-
ies is an essential feature of systematic reviews.1–3 A recent review
showed that lack of adherence to a priori defined validity criteria
may help explain why primary studies on the same topic provide
different results.4 Some key issues still remain unresolved: which
checklists and scales are the ideal approaches5 and how the
results of quality assessment in a systematic review should be
handled in the analysis and interpretation of results.6–10
We compared the approaches used for quality assessment of
primary studies by Cochrane systematic reviews with systematic
reviews published in paper based journals. We determined how
quality assessment is used and whether systematic reviews
consider quality assessment in their results.
Methods
We sampled systematic reviews from two databases in the
Cochrane Library: the Cochrane Database of Systematic
Reviews, which includes reviews prepared by review groups of
the Cochrane Collaboration; and the Database of Abstracts of
Reviews of Effectiveness (DARE), which selects systematic
reviews published in peer reviewed journals on the basis of their
adherence to a few methodological requirements.11
We stratified all 1297 Cochrane systematic reviews published
in issue 1, 2002, of the Cochrane Library by type of intervention
(six levels: drugs; rehabilitation or psychosocial; prevention or
screening; surgery or radiotherapy intervention; communica-
tion, organisational, or educational; other) and by Cochrane
review group (50 levels). We used a computer generated
randomisation scheme to select at least 50% of the systematic
reviews in each cell. Our final sample represented 62.4%
(n = 809) of the Cochrane reviews. The paper based systematic
reviews were extracted from DARE, including all systematic
reviews published in 2001 registered up to November 2002.
Data extraction form
We assessed the systematic reviews by using an ad hoc data
extraction form. We developed this form by taking into account
published reports on the quality assessment of trials included in
systematic reviews.1 2 4–10 12–28
We did not aim at standardised operational definitions of the
quality measures but accepted at face value what was reported by
the authors of individual studies. As a common taxonomy for
quality assessment does not exist, we used a large number of
descriptive quality components to capture as many of the differ-
ent definitions as possible.
For each systematic review we sought general information
(title, authors, publication date, type of intervention, and
presence of a meta-analysis). We then evaluated what authors
reported in the methods section of their review for quality
assessment. In particular, we tried to ascertain whether authors
stated they would have assessed the quality and how (scale or
checklist, components studied, composite score) and in what way
they planned to use the quality assessment (for example, as
exclusion criteria, for sensitivity analysis). See bmj.com for a
summary version of the data extraction form.
We then evaluated how authors assessed quality.We recorded
if trials were combined in a quantitative meta-analysis; if the
quality was evaluated; if scales, checklists, and scores were used;
and how the quality was formally incorporated. Assessors judged
whether an attempt had been made to incorporate the quality
assessment in the results, either qualitatively or quantitatively.
Summary version of data extraction form is on bmj.com
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We purposely did not make our operationalised definition of
qualitative too stringent. If authors made some comments or dis-
cussed the results with reference to the quality of trials then we
considered this sufficient to classify the systematic review as hav-
ing incorporated qualitatively the quality assessment.
Our definition of quantitative was more stringent and
included the carrying out of a sensitivity or subgroup analysis
(with quality as a stratifying factor) and use of a quality score as a
weight or factor for cumulative meta-analysis or metaregression.
Data extraction
We developed a draft of an extraction checklist and piloted it on
40 randomly selected Cochrane reviews. The checklist was
revised and an instruction manual prepared. The checklist was
further tested on another random sample of 130 systematic
reviews, and further refinements were incorporated. Inter-rater
agreement, based on a random sample of 5% of the Cochrane
reviews and paper based reviews (48 reviews), was high.
Inter-rater reliability was moderate to perfect (percentage mean
agreement 94, range 71.1-100; prevalence and bias adjusted 
statistic mean 0.80, range 0.40-1.00).
Twelve pairs of investigators independently extracted the
data. Disagreements were resolved through discussion and, when
necessary, centrally reviewed.
Statistical analysis
Owing to the frequent imbalance of marginals in our
contingency matrix, we used a prevalence and bias adjusted 
statistic to assess inter-rater reliability.29 30 We report confidence
intervals of differences between proportions and P values of 2
tests.
Results
We analysed 965 systematic reviews: 809 Cochrane reviews and
156 reviews published in paper based journals (figure). Quality
assessment was assessed in 854 (88.5%) of the reviews and was
more often carried out in Cochrane reviews than in paper based
reviews (93.9% v 60.3%, P < 0.0001; table 1). The same was true
when we compared the proportions of reviews using quality
assessment in an informal fashion (90.5% v 51.9%; P < 0.0001;
table 2). The formal approaches most used by both types of
review were exclusion criteria (12%), sensitivity analysis (10%),
exploration of heterogeneity (8%), and subgroup analysis (4%).
The quality components most frequently assessed were, in
decreasing order, allocation concealment, blinding, and losses to
follow-up. The difference between Cochrane reviews and paper
based reviews for these and intention to treat analysis
significantly favoured Cochrane reviews (table 3).
The most commonly used quality scale was the Jadad scale
(n = 113, 11.7%; table 3). Cochrane reviews used the scale less
often than paper based reviews. In 65.0% (n = 526) of Cochrane
reviews and 48.1% (n = 75) of paper based reviews, authors car-
ried out the quality assessment using single components rather
than a formal scale.
No significant differences emerged when Cochrane reviews
and paper based reviews were analysed separately by type of
intervention assessed—for example, drug compared with
non-drug interventions.
Utilisation of quality assessment
We found that 496 systematic reviews (51.4%) linked quality to
the interpretation of results, with no difference in the
proportions of Cochrane reviews and paper based reviews
(51.8% v 49.4%, P = 0.58; table 1). This also held true for the sub-
group analysis of drug compared with non-drug interventions.
Is quality assessment carried out as stated?
The authors of Cochrane reviews were more likely than those of
paper based reviews to state that they would assess quality (93.7%
v 63.5%) yet did not always do so (table 1). About 5% of system-
atic reviews in each group carried out quality assessment despite
not being explicitly stated in the methods. Finally, only 328
(33.9%) of the systematic reviews formally specified how they
planned to use the quality assessment in the methods (for exam-
ple, for sensitivity analysis, exclusion criteria): 36.0% (n = 291) of
Cochrane reviews and 23.7% (n = 37) of paper based reviews
(P = 0.79).
Discussion
More than 50% of systematic reviews (both Cochrane reviews
and reviews based in paper articles) did not specify in the meth-
ods whether and how they would use quality assessment in the
analysis and interpretation of results. Cochrane reviews fared
better than paper based reviews in carrying out quality
assessment but were equally unsuccessful in taking it into
account.
Since 1987 several authors have explored the extent to which
systematic reviews and meta-analyses incorporate quality assess-
ment into the results, with unsatisfactory findings.22 31–34 Moher et
al analysed 240 systematic reviews19: quality assessment was car-
ried out more often in Cochrane reviews than in reviews
published in paper based journals (36/36, 100% v 78/204, 38%;
P < 0.001), although only 29 took such assessment into account
during their analysis (paper based reviews 27/78 34% v
Cochrane reviews 2/36 6%; P < 0.001).
Total No of systematic reviews
Cochrane reviews (n=809)
Paper based reviews (n=156)
Authors would assess quality
Cochrane reviews (n=758)
Paper based reviews (n=99)
Authors did not state they would assess quality
Cochrane reviews (n=51)
Paper based reviews (n=57)
Authors assessed quality
Cochrane reviews (n=720)
Paper based reviews (n=86)
Authors linked results to quality assessment
Cochrane reviews (n=403)
Paper based reviews (n=73)
Authors did not assess quality
Cochrane reviews (n=38)
Paper based reviews (n=13)
Authors assessed quality
Cochrane reviews (n=40)
Paper based reviews (n=8)
Authors linked results to quality assessment
Cochrane reviews (n=16)
Paper based reviews (n=4)
Authors did not assess quality
Cochrane reviews (n=11)
Paper based reviews (n=49)
Flow of systematic reviews through trial
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During the past 15 years research has concentrated on two
main issues: which components of the quality assessment (for
example, allocation concealment) are predictive of valid results
and what tool (scales or checklists) best assesses quality. In 2003
Egger et al found that allocation concealment and double blind-
ing were strongly related to treatment effects.4 20 35 Despite the
dozens of quality scales and checklists that have been
proposed,5 7 18 the answer is still unclear and many doubt that a
generic quality assessment tool that would prove valid in all cases
can ever be found. In our study the most frequently used tool was
the Jadad scale, a tool that has been criticised for its low sensitiv-
ity and that does not consider allocation concealment because it
was developed before the importance of concealment was estab-
lished.21 Moreover, less attention has been paid to explore how
quality can be used in the interpretation of the results of system-
atic reviews.8 9 13 36
As Cochrane reviews are preceded by a published protocol
and the Cochrane handbook mandates that some form of qual-
ity assessment of primary studies is to be done,37 it is not surpris-
ing that authors of Cochrane reviews state that they will carry out
quality assessment and do so. Yet when it comes to the more
complex, yet potentially relevant, aspect of incorporating quality
into the results, Cochrane reviews fared no better than their
paper based counterpart.
These findings may have several explanations. That
Cochrane reviews provide more details may be due to the
absence of limitations on space in electronic publications;
however, most of the medical journals now publish a web version
of their papers, with different space restrictions. We investigated
this potential of the electronic versions but found that none of
the paper based reviews was supplemented with an electronic
appendix of quality assessment. It is also possible that authors
are unaware of, or that editors are not interested in, publishing
extensive electronic versions. Moreover, most authors of paper
based articles may be aware of space limitations imposed by
journals and thus omit details of quality assessment because they
believe that they not are relevant to their results. This could be a
reflection of a bad practice: a more common use of unplanned
outcome dependent subgroup analyses. Where subgroup analy-
ses are not predefined, the risk exists that data may have been
Table 1 Distribution of three main quality assessment related variables investigated in study according to Cochrane systematic reviews and systematic
reviews published in paper based journals. Values are numbers (percentages) unless stated otherwise
Variable
Cochrane systematic reviews
(n=809)
Paper based systematic reviews
(n=156) Difference between proportions (95% CI) P value (2 test)
Authors would carry out quality
assessment
758 (93.7) 99 (63.5) 30.2 (22.5 to 38.0) <0.0001
Quality assessment carried out 760 (93.9) 94 (60.3) 33.6 (25.8 to 41.5) <0.0001
Quality assessment linked to results 419 (51.8) 77 (49.4) 2.4 (−6.1 to 11.0) 0.5777
Table 2 Summary of approaches to quality assessment and formal quantitative analyses related to quality assessment used in Cochrane systematic reviews
and systematic reviews published in paper journals. Values are numbers (percentages) unless stated otherwise
Approaches used to incorporate
quality assessment*
Cochrane systematic reviews
(n=809)
Paper based systematic
reviews (n=156)
Cochrane and paper
based reviews
Difference between proportions
(95% CI) P value (2 test)
Informal:
General comment 732 (90.5) 81 (51.9) 813 (95) 38.6 (30.5 to 46.7) <0.0001
Formal:
Exclusion criteria 102 (12.6) 9 (5.8) 111 (12) 6.8 (2.5 to 11.2) 0.0142
Exploration of heterogeneity 63 (7.8) 11 (7.1) 74 (8) 0.7 (−3.7 to 5.2) 0.7517
Subgroup analysis 29 (3.6) 8 (5.1) 37 (4) −1.5 (−5.2 to 2.1) 0.3580
Sensitivity analysis 89 (11.0) 9 (5.8) 98 (10) 5.2 (1.0 to 9.5) 0.0476
Weighting of estimates 1 (0.1) 0 — 0.1 (−0.1 to 0.4) 0.6604
Cumulative meta-analysis 1 (0.1) 0 — 0.1 (−0.1 to 0.4) 0.6604
*More than one answer possible.
Table 3 Summary of quality components and quality scales most used in Cochrane systematic reviews and systematic reviews published in paper based
journals analysed in study. Values are numbers (percentages) unless stated otherwise
Variable
Cochrane systematic reviews
(n=809)
Paper based systematic reviews
(n=156) Difference between proportions (95% CI) P value (2 test)
Quality components*:
Allocation concealment 639 (79.0) 37 (23.7) 55.3 (48.0 to 62.5) <0.0001
Any type of blinding 604 (74.7) 64 (41.0) 33.7 (25.4 to 41.9) <0.0001
Generation of allocation sequence 209 (25.8) 26 (16.7) 9.1 (2.6 to 15.8) 0.0146
Similarity of groups at baseline 142 (17.6) 17 (10.9) 6.7 (1.1 to 12.2) 0.0402
Description of outcomes 110 (13.6) 14 (9.0) 4.6 (−0.5 to 9.7) 0.1142
Intention to treat analysis 240 (29.7) 19 (12.2) 17.5 (11.5 to 23.5) <0.0001
Sample size 99 (12.2) 24 (15.4) −3.2 (−9.2 to 3.0) 0.2805
Losses to follow-up 561 (69.3) 52 (33.3) 36.0 (28.0 to 44.1) <0.0001
Quality scale:
Schulz 37 (4.6) 2 (1.3) 3.3 (1.0 to 5.6) 0.0560
Jadad 84 (10.4) 29 (18.6) −8.4 (−14.9 to −2.0) 0.0025
Cochrane Group 133 (16.4) 0 (0) 16.4 (13.9 to 19.0) <0.0001
Other 35 (4.3) 20 (12.8) −8.5 (−13.9 to –3.1) <0.0001
*More than one answer possible.
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dredged in search of a significant result.38 Cochrane systematic
reviews are, at least in principle, protected against post hoc
analyses through the preliminary publication of a detailed study
protocol.
Limitations of the study
One limitation of our study is that the Cochrane reviews were
published between 1995 and 2002, whereas the paper based
articles were first published in 2001. Although older, the
Cochrane reviews still fared better for frequency of quality
assessment. The Cochrane reviews were, however, remiss in their
efforts to incorporate the quality assessment findings in the
presentation and interpretation of results. We believe that this
difference in publication dates did not affect our results because
between 1995 and 2000 no major methodological advances or
new consensus emerged in the literature on systematic reviews.
Another limitation is whether DARE39 was an appropriate source
from which to sample paper based articles. This is a legitimate
concern as it may have led to the selection of a control group
with better than average quality. Any selection bias would move
our estimate towards the null effect or would minimise the
difference between the two types of reviews. Thus, our results
could be understated.
A third possible limitation is that incomplete reporting might
have influenced our assessment. Evidence, however, suggests that
what is reported about important aspects of the conduct of a
study typically do reflect what is actually done.40 41
Finally, we assessed quality assessment using a checklist that
had been developed ad hoc. Although the lack of validation may
be criticised, we believe that the items have good face validity: we
attempted to reduce assessors’ subjectivity, and the inter-rater
reliability was acceptably high. We did have trouble with the clas-
sification of quality items, tools, and approaches, as there are
innumerable ways to define study quality.7 20 It is possible that we
recorded quality data with slightly different meanings from those
intended by the authors of the studies. Given that almost all sys-
tematic reviews were incomplete in their reporting and given the
narrative nature of the quality assessment, it is likely that our
checklist may have had decreased ability to reflect what authors
truly wanted to do and did. It was beyond the scope of our study
to assess the appropriateness of the methods chosen for quality
assessment by the authors.
Conclusions
Within the Cochrane Collaboration there is room for better
standardisation of approaches to quality assessment. The
Cochrane handbook should provide clearer guidelines on how
to do it. Less clear is how to improve quality assessment in arti-
cles published in paper based journals. For such reviews,
improvement may only come once a consensus of methodology
for systematic reviews has been decided. Peer reviewers and edi-
tors should scrutinise systematic reviews to ensure consistency
among the various sections and to avoid outcome dependent
analyses.
We believe that more research is needed to understand how
best to assess and incorporate the methodological quality of pri-
mary studies into the results of systematic reviews. Progress
towards the necessary improvements highlighted by the results
of this study may come from two international meetings planned
in May and June 2005 that will be dedicated to, respectively, an
improvement of the current section of the Cochrane handbook
on quality assessment in systematic reviews and a revision of the
QUOROM statement.2
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